NDA 211288 · Pfizer
Vizimpro
Dacomitinib · Oral
NovelPriority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Dec 18, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Sep 27, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
55
4 Phase 3, 4 recruiting
FAERS reports
749
692 serious, 330 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 23, 2026.
VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. ( 1 )
Mechanism: Dacomitinib is an irreversible inhibitor of the kinase activity of the human EGFR family (EGFR/HER1, HER2, and HER4) and certain EGFR activating mutations (exon 19 deletion or the exon 21 L858R substitution mutation). In vitro dacomitinib also inhibited the activity of DDR1, EPHA6, LCK, DDR2, and MNK1 at clinically relevant concentrations. Dacomitinib demonstrated dose-dependent inhibition of EGFR and HER2 autophosphorylation and tumor growth in mice bearing subcutaneously implanted human tumor xenografts driven by HER family targets including mutated EGFR. Dacomitinib also exhibited...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 27, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
3 products under this application
- VIZIMPRO · DACOMITINIB 30MG · TABLET, ORAL · Discontinued
- VIZIMPRO · DACOMITINIB 45MG · TABLET, ORAL · Discontinued
- VIZIMPRO · DACOMITINIB 15MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Dacomitinib" as an intervention, any sponsor and status, largest first.
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung CancerPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01360554 · 878 participants · Start Jun 16, 2011 · Primary completion Sep 30, 2013
Drug: Dacomitinib (PF-00299804); Active Comparator (erlotinib) and 2 more · For: Non-Small Cell Lung Cancer
Sites: Birmingham, Alabama; Florence, Alabama; Mobile, Alabama · 224 sites in all
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT04423185 · 770 participants (planned) · Start Aug 15, 2020 · Primary completion Jul 1, 2026
Drug: Almonertinib 110 MG; Dacomitinib 45 MG and 9 more · For: Rare Tumor
Sites: Beijing, China
- PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic CancerPivotal-lookingCompleted
NCIC Clinical Trials GroupResearch network
NCT01000025 · 720 participants · Start Dec 23, 2009 · Primary completion Jan 15, 2014
Drug: PF-00299804; Placebo · For: Lung Cancer
Sites: Arcadia, California; Skokie, Illinois; Buenos Aires, Argentina · 89 sites in all
- ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01774721 · 452 participants · Start May 9, 2013 · Primary completion Jul 29, 2016
Drug: Dacomitinib (PF-00299804); Gefitinib · For: Non-small Cell Lung Cancer With EGFR-Activating Mutations
Sites: Beijing, China; Changchun, China; Changsha, China · 52 sites in all
PfizerPfizer (PFE)
NCT01465802 · 236 participants · Start Dec 26, 2011 · Primary completion May 18, 2015
Drug: Dacomitinib; Dacomitinib and 3 more · For: Non Small Cell Lung Cancer (NSCLC)
Sites: Duarte, California; Fullerton, California; Irvine, California · 81 sites in all
- EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyPivotal-lookingRecruiting
Region SkaneAcademic, hospital or other
NCT06486142 · 200 participants (planned) · Start Sep 21, 2022 · Primary completion Sep 2028
Drug: Afatinib/Dacomitinib; Osimertinib · For: Non-Small Cell Lung Cancer
Sites: Lund, Sweden
- A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy RegimenPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00769067 · 188 participants · Start Nov 2008 · Primary completion Oct 2010
Drug: Erlotinib; PF-00299804 · For: Non-small Cell Lung Cancer
Sites: Muscle Shoals, Alabama; Montebello, California; Bridgeport, Connecticut · 59 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death238
- diarrhoea121
- rash115
- neoplasm progression78
- paronychia58
- blood pressure increased47
- malignant neoplasm progression45
- pruritus36
- off label use34
- dyspnoea32
- decreased appetite29
- vomiting28
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2012 | 11 |
| 2013 | 14 |
| 2014 | 8 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 50 |
| 2020 | 77 |
| 2021 | 131 |
| 2022 | 207 |
| 2023 | 128 |
| 2024 | 55 |
| 2025 | 41 |
| 2026 | 16 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Jun 8, 2026
Vizimpro, Tablet, 15 mg (NDC 0069-0197-30). Discontinuation of the manufacture of the drug
To Be Discontinued · updated Jun 8, 2026
Vizimpro, Tablet, 45 mg (NDC 0069-2299-30). Discontinuation of the manufacture of the drug
To Be Discontinued · updated Jun 8, 2026
Vizimpro, Tablet, 30 mg (NDC 0069-1198-30). Discontinuation of the manufacture of the drug
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vizimpro (Dacomitinib)
2024 spending
$2.6M
Beneficiaries
37
163 claims
Per beneficiary
$70,021
$516.82 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,488,810 |
| 2021 | $2,472,649 |
| 2022 | $2,379,396 |
| 2023 | $2,774,626 |
| 2024 | $2,590,793 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Wu YL, Cheng Y, Zhou X, et al. · Lancet Oncol 2017 · Clinical Trial, Phase III, Comparative Study
- Dacomitinib Beats Gefitinib for EGFR+ NSCLC.
· Cancer Discov 2017 · Clinical Trial, Phase III
- Bioequivalence study of dacomitinib and Vizimpro® in healthy Chinese volunteers under fasting and fed conditions: A randomized, open-label, single-dose, crossover trial.
Yang X, Li J, Zhang T, et al. · Clin Transl Sci 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.
David GM, Maria Del Pilar BC, Cristina MR · J Oncol Pharm Pract 2023 · Systematic Review
- Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
Zhao Y, Liu J, Cai X, et al. · BMJ 2019 · Systematic Review, Network Meta-Analysis
- Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study.
Jung HA, Park S, Lee SH, et al. · ESMO Open 2023 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.